The biotech firm is currently testing its primary drug candidate, BBT001, in clinical trials across the U.S., Australia, Europe, and New Zealand to treat moderate-to-severe atopic dermatitis. Simultaneously, the company has launched a Phase 2a trial in China targeting chronic spontaneous urticaria. These efforts are backed by principal stockholders including Salvia Investment and affiliates of RA Capital and Biotechnology Value Fund.
In section Market Quotes
Bambusa Therapeutics Targets Nasdaq Debut Amid Clinical Expansion
With no revenue to its name and an accumulated deficit of $77.2 million, biopharmaceutical firm Bambusa Therapeutics has filed for an initial public offering. The company intends to list on the Nasdaq Global Select Market under the ticker BBTX, seeking capital to fuel its pipeline of bispecific antibodies for inflammatory diseases.
Despite these developments, the company remains in the pre-revenue stage. Bambusa has yet to disclose the intended size of its offering or a target price range for its shares, leaving investors to await further filings regarding the valuation of its specialized immunology assets.
Comments (0)
No comments yet. Be the first!